Suppr超能文献

分泌型PCSK9降低HepG2细胞中低密度脂蛋白受体水平并不需要催化活性。

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

作者信息

McNutt Markey C, Lagace Thomas A, Horton Jay D

机构信息

Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

出版信息

J Biol Chem. 2007 Jul 20;282(29):20799-803. doi: 10.1074/jbc.C700095200. Epub 2007 May 29.

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed approximately 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.

摘要

前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)是枯草杆菌蛋白酶家族中蛋白酶K亚家族的成员,它在与肝细胞表面的低密度脂蛋白受体(LDLR)结合后,促进其内化和降解。PCSK9具有自催化活性,可释放该蛋白N端的前结构域。在前结构域与催化结构域的复合物通过分泌途径时,前结构域仍与催化结构域紧密结合。目前尚不清楚PCSK9降低LDLR的作用是否需要酶活性。在此,我们在细胞中共同表达了前结构域和无催化活性的蛋白酶结构域,并从培养基中纯化了该蛋白。当以生理浓度添加到人类肝癌HepG2细胞的培养基中时,无催化活性的PCSK9结合和降解LDLR的能力与野生型蛋白相似。同样,功能获得性突变体PCSK9(D374Y)的催化失活版本与具有催化活性的对应物相比,活性没有丧失;与野生型PCSK9相比,这两种蛋白在降解细胞表面LDLR方面的活性均增加了约10倍。我们得出结论,PCSK9降解LDLR的能力与催化活性无关,并表明PCSK9作为伴侣蛋白发挥作用,以防止LDLR循环利用和/或将LDLR靶向溶酶体降解。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验